Palvella Therapeutics (PVLA) Asset Writedowns and Impairment (2023)
Palvella Therapeutics (PVLA) posted quarterly Asset Writedowns and Impairment of -$981000.0 for Q4 2023, down 106.59% quarter-over-quarter from $14.9 million in Q3 2023.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Asset Writedowns and Impairment (2023) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Asset Writedowns and Impairment for 1 consecutive years, with -$981000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Asset Writedowns and Impairment changed N/A year-over-year to -$981000.0; the TTM figure through Sep 2024 stood at $13.9 million (changed N/A YoY), while the FY2023 annual figure was $13.9 million, changed N/A from the prior year.
- Asset Writedowns and Impairment declined to -$981000.0 in Q4 2023 per PVLA's latest filing, from $14.9 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $14.9 million in Q3 2023 and bottomed at -$981000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - |